Home News BioInvent selected to present at ASCO in Chicago

BioInvent selected to present at ASCO in Chicago

BioInvent utvalt att presentera vid ASCO i Chicago

BioInvent selected to present at ASCO in Chicago

29 April, 2024

BioInvent has been selected to present two posters at the American Society for Clinical Oncology Annual Congress (ASCO 2024) in Chicago from May 31 to June 4. The presentations will focus on data from the company’s clinical studies with the lead drug candidates BI-1808 and BI-1206, both in phase I/IIa development in combination with MSD’s Keytruda. BI-1808 is also evaluated as single agent, which will also be included in the presentation.

BioInvent has developed several antibody candidates currently in clinical development, both as monotherapy and in combination with today’s standard treatments. The two lead drug candidates, BI-1206 and BI-1808, are being tested in phase I/IIa studies for the treatment of non-Hodgkin’s lymphoma (NHL) and solid tumours.

The company’s research suggests that first-in-class immunomodulatory antibodies have the potential to enhance the efficacy of standard treatment such as various immunotherapies and improve the outcome of cancer treatment.

BioInvent has three additional products, BT-001, BI-1607 and BI-1910, in early clinical studies, as potential treatments for several cancer types. In addition, the Lund-based biotech company has out-licensed five clinical projects to other companies.

Clinical data will be presented at ASCO 2024

BioInvent has been selected to present two posters for BI-1808 and BI-1206 at the American Society for Clinical Oncology annual congress (ASCO 2024) in Chicago, Illinois, from May 31 to June 4.

The two poster presentations will report initial combination data from the phase I/IIa study with BI-1808 in combination with MDS’s Keytruda, as well as an update from the monotherapy arm. They will also present combination data from the phase I/IIa study with BI-1206 in combination with Keytruda for the treatment of patients with solid tumours.

“These presentations represent the start of a data-rich year for BioInvent and build on the promising initial results from each program reported in 2023. We continue to advance the clinical development of both BI-1808 and BI-1206 and look forward to seeing the first Phase 2 data for BI-1808 and BI-1206 by year-end 2024.” – Martin Welschof, CEO BioInvent 

Progress during Q1

BioInvent has also published the interim report for Q1. The company ended the quarter with a strong financial position of SEK 1219 million in cash and investments, which CEO Martin Welschof commented on in the report:

– BioInvent remains well-financed with sufficient funds to allow us to achieve the communicated upcoming inflection points in the coming year. A dynamic first quarter has provided a strong start to the year, and we have much to look forward to in the months ahead.

In January, BioInvent regained the rights to immune-oncology targets from partner Exelixis, followed by a supply agreement with AstraZeneca in February where BI-1206 will be evaluated in a phase IIa triple-combination study adding Calquence to the BI-1206 + rituximab mix in patients with NHL.

In March, BioInvent’s partner CASI Pharmaceuticals announced positive preliminary efficacy data from a phase I dose escalation and expansion study of BI-1206 in combination with rituximab. In a press release, CASI stated that the study showed impressive signs of clinical efficacy, with four partial responses and one complete response out of eight evaluable patients. Read more here.

A month later, BioInvent signed a fourth clinical collaboration and supply agreement with MSD. The agreement involves an evaluation of BioInvent’s BI-1910 in combination with MSD’s Keytruda in the second part of the phase I/IIa study for the treatment of solid tumours.

– This is our fifth product in ongoing clinical trials, demonstrating the capacity of BioInvent’s technology to identify novel, first-in-class therapeutic cancer targets, CEO Martin Welschof concluded.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev